Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Benefits"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
dewey-ones:"330 - Economics"
dewey-ones:"610 - Medicine & health"
language:"English"
Showing
1
-
20
of
76
Search:
'"Benefits"'
,
query time: 0.02s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses : an economic analysis and budget impact analysis
by
Membe, Stephen K.
Published 2011
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
2
Switching from innovator to biosimilar (subsequent entry) infliximab : an updated review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
3
Deep brain stimulation for Parkinson's disease : a review of clinical effectiveness, cost-effectiveness, and guidelines
by
Lachance, Chantelle
,
Spry, Carolyn
,
MacDougall, Danielle
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
4
CADTH Canadian Drug Expert Committee recommendation: Nusinersen (Spinraza -- Biogen Canada Inc.) : indication : treatment of 5q spinal muscular atrophy
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
5
Telehealth for patients with hypertension, coronary artery disease or implantable cardiac devices : a review of the clinical effectiveness, cost-effectiveness and guidelines
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
6
CADTH Canadian Drug Expert Committee recommendation: Nusinersen (Spinraza -- Biogen Canada Inc.) : indication : treatment of 5q spinal muscular atrophy
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
7
CADTH Canadian Drug Expert Committee recommendation: Cysteamine delayed-release (Procysbi -- Horizon Pharma Ireland Ltd.) : indication : nephropathic cystinosis
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
8
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
9
Trauma-informed care for adults involved in the correctional system : a review of the clinical effectiveness, cost-effectiveness, and guidelines
by
Williams, D.
,
Frey, Nina
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
10
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
11
CADTH Canadian Drug Expert Committee recommendation: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Symtuza -- Janssen Inc.) : indication: treatment of HIV type 1 (HIV-1...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
12
CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
13
CADTH Canadian Drug Expert Committee recommendation: Nitisinone (nitisinone tablets -- Cycle Pharmaceuticals Ltd.) : indication : the treatment of adult and pediatric patients with...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
14
CDEC final recommendation: Tiotropium bromide (Spiriva respimat -- Boehringer Ingelheim Canada Ltd.) : indication : chronic obstructive pulmonary disease
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
15
CADTH Canadian Drug Expert Committee recommendation: Nitisinone (nitisinone tablets -- Cycle Pharmaceuticals Ltd.) : indication : the treatment of adult and pediatric patients with...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
16
CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
17
CADTH Canadian Drug Expert Committee recommendation: Brexpiprazole (Rexulti - Lundbeck Canada Inc and Otsuka Canada Pharmaceutical Inc.) : indication : treatment of schizophrenia i...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
18
CDEC final recommendation: Tiotropium bromide (Spiriva respimat -- Boehringer Ingelheim Canada Ltd.) : indication : chronic obstructive pulmonary disease
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
19
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis
Published 2020
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
20
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
1
2
3
4
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Classification: 330 - Economics
Clear Filter
Classification: 610 - Medicine & health
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
330 - Economics
610 - Medicine & health
140 - Specific philosophical schools
7
700 - The arts; fine & decorative arts
7
600 - Technology
2
100 - Philosophy & psychology
1
Language
English
Collection
National Center for Biotechnology Information
76
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
48
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
5
Argáez, Charlene
2
Campbell, Kaitryn
2
Ford, Caitlyn
2
more ...
Gray, Casey
2
Ho, Chuong
2
Kanga, Ismat
2
Young, Calvin
2
Adcock, Lorna
1
Chao, Yi-Sheng
1
Frey, Nina
1
Lachance, Chantelle
1
MacDougall, Danielle
1
Membe, Stephen K.
1
Spry, Carolyn
1
Thompson, Wade
1
Visintini, Sarah
1
Williams, D.
1
see all ...
less ...
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=dewey-ones%3A%22330+-+Economics%22&filter%5B%5D=dewey-ones%3A%22610+-+Medicine+%26+health%22&filter%5B%5D=language%3A%22English%22&lookfor=%22Benefits%22&type=Subject
Send by Email
×
Loading...